2022
DOI: 10.21203/rs.3.rs-2132531/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Long-term survival and immune reconstitution of chimeric antigen receptor T-cell therapy for childhood molecular relapse of B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Abstract: Measurable residual disease (MRD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an independent risk factor for relapse in patients with acute lymphoblastic leukemia (ALL). This study aimed to assess the efficacy, safety, and immune reconstitution of chimeric antigen receptor T-cell (CAR-T) therapy in patients with molecular relapse after allo-HSCT. Eleven patients with molecular relapse of B-cell-ALL who underwent CAR-T therapy after allo-HSCT were enrolled. The rate of MRD negativity… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 26 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?